The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 4 September 2007, www.theannals.com, DOI 10.1345/aph.1K362.
 The Annals of Pharmacotherapy: Vol. 41, No. 10, pp. 1725-1727. DOI 10.1345/aph.1K362
© 2007 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in The Annals
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dufresne, R. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dufresne, R. L

Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics

Robert L Dufresne, PhD BCPS BCPP

Professor of Pharmacy, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI; Psychiatric Pharmacotherapy Specialist, Veterans Affairs Medical Center, Providence, RI

Reprints: Dr. Dufresne, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Fogarty Hall, 41 Lower College Rd., Kingston, RI 02881, fax 401/874-2181, rdu3990u{at}postoffice.uri.edu

Of all the metabolic effects of some of the atypical second-generation antipsychotics, their potential to induce glucose dysregulation has induced a storm of controversy over the past several years. The numerous published epidemiologic studies are difficult to interpret due to the high background rate of type 2 diabetes mellitus in this population, the inherent problems with analysis of observational data, and the short duration of the available studies. A plan to monitor for weight gain, hypertriglyceridemia, glucose dysregulation, and other potential adverse metabolic effects resulting from antipsychotic treatment is critical.

Key Words: antipsychotic, diabetes mellitus, hypertriglyceridemia, obesity

Published Online, September 4, 2007. www.theannals.com, DOI 10.1345/aph.1K362

Related articles in The Annals:

Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Leslie L Citrome, Richard IG Holt, Woodie M Zachry, Jerry D Clewell, Paul A Orth, Jamie L Karagianis, and Vicki Poole Hoffmann
The Annals 2007 41: 1593-1603. [Abstract] [Full Text]  





homecopy help contact us subscription past issues search current issue
Copyright © 2007 by Harvey Whitney Books Company.